Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer

Sònia Gatius1,2,*, Mariona Jove3,†, Cristina Megino-Luque1,2, Manel Albertí-Valls1, Andree Yeramian1,2, Nuria Bonifaci1,2, Miquel Piñol1, Maria Santacana2,‡, Irene Pradas3, David Llobet-Navas2,5, Reinald Pamplona3,4, Xavier Matías-Guiu1,2,5,6,‡ and Núria Eritja2,7,*,‡

Abstract: Uterine serous carcinoma is considered a rare and aggressive variant of endometrial cancer that accounts for 10% of all endometrial cancers diagnosed but is responsible for 40% of endometrial cancer-related deaths. Unfortunately, current treatments for serous endometrial carcinoma are ineffective. Therefore, there is a need to find new therapeutic targets. The aim of this study was to analyse the metabolic profile of serous cancer in order to identify new molecules and thereby define potential therapeutic targets. We observed that most of the differential metabolites are lipid species (suggesting the important role of the lipid metabolism). In addition, we found an increase in 2-Oxo-4-methylthiobutanoic acid (synthesised by the ADI1 enzyme) in serous carcinomas. Using public database analysis and immunohistochemistry, we established a correlation between elevated ADI1 levels and serous carcinoma. Furthermore, the ectopic modification of ADI1 expression in vitro revealed the ability of ADI1 to induce pathological cell migration and invasion capabilities.

Keywords: endometrial cancer; acireductone dioxygenase 1; serous carcinoma; lipid metabolism; metabolomics; therapeutic targets.
dioxygenase 1 (ADI1 enzyme), which showed higher levels in SCs. To further investigate the role of ADI1 in SC, we analysed the expression protein levels of ADI1 in 96 ECs (67 EECs and 29 SCs), proving that the levels of ADI1 were higher in SCs compared to EECs. We also found that ADI1 mRNA levels were higher in p53 abnormal ECs compared to p53 wild type tumours. Furthermore, elevated ADI1 mRNA levels showed a statistically significant negative correlation with overall survival and progression-free survival among EEC patients. Finally, we tested the ability of ADI1 to induce migration and invasion capabilities in EC cell lines. Altogether, these results suggest that ADI1 could be a potential therapeutic target in poor-prognosis SCs and other ECs with abnormal p53 expression.

Keywords: serous endometrial cancer; metabolomics profile; bioactive lipid species; ADI1; endometrial cancer

1. Introduction

Endometrial cancer (EC) is the most common gynecologic malignancy worldwide, with approximately 417,367 newly diagnosed cases and 97,370 deaths in 2020 [1]. Additionally, the incidence of endometrial carcinoma is estimated to increase by 1–2% yearly [2]. EC is a disease that predominantly afflicts postmenopausal women (who represent 90% of patients diagnosed with EC cancer). However, 10% of cases are diagnosed in premenopausal women (5% of whom are under the age of 40) [3]. Although most ECs are diagnosed at early stages and cured with surgery alone, nearly 20% of EC cases recur after surgery to vaginal or pelvic regions, often metastasizing to distant sites [4]. The EC mortality rate relies on a subset of parameters and features present at diagnosis, including histological type, advanced stage and/or grade or lympho-vascular invasion. Moreover, those patients showing high-risk tumour features at diagnosis receive adjuvant radiation, chemotherapy or both. However, these treatments are estimated to benefit only 10–15% of all patients and, consequently, the median survival rates of patients with recurred or advanced EC are poor, with rates of less than one year [5].

Establishing the histological type of EC has consistently proven to be an important predictor of survival and the extent of the initial surgical procedure. Classically, histological and pathological evaluation classifies EC into endometrioid (EEC) and non-endometrioid (NEEC) tumours. EECs account for about 85% of EC cases and are usually associated with peri-menopausal and post-menopausal women, estrogen exposition, obesity and endometrial hyperplasia. Generally, EEC tumours have good prognoses [6]. In contrast, NEECs are very aggressive, oestrogen-independent tumours that usually arise in endometrial polyps in atrophic endometrium at older ages and present worse prognoses than EEC [7]. Serous carcinoma (SC) is the prototype of NEECs and accounts for less than 10% of all ECs; however, SC represents ≈40% of total EC deaths [8]. A new classification of EC from The Cancer Genome Atlas (TCGA) has provided additional (and potentially superior) prognosis information to traditional histologic typing and grading. Thus, through integrative genomic exome sequence analysis, the TCGA has revealed the existence of four different groups of EC tumours: Group 1, comprising EECs with mutations in the exonuclease domain of the DNA polymerase epsilon (POLE) and associated with good prognosis; group 2, including EECs with microsatellite instability; group 3, including EECs with low copy-number alterations (both groups 2 and 3 show similar progression-free survival rates, halfway between groups 1 and 4); and group 4 (copy-number high or serous-like), comprising most endometrial serous cancers and one quarter of the grade 3 endometrioid cases, with high numbers of gene copy-number alterations and p53 mutations and worse prognoses [9].

However, this molecular classifier does not replace clinicopathologic risk assessment and today it is thought that the integration of molecular classification into pathologic diagnosis may be important in the context of improving the prognosis and clinical management of EC patients [10,11].
Extensive research using high-throughput technologies including proteomics, transcriptomics and genomics has increased the characterisation of molecular changes at different levels of cellular expression specifically associated with human endometrium and the onset and progression of EC [12,13]. Metabolomics is believed to have the potential to reflect the phenotype of the cell more precisely and to provide more fundamental and global information than genomics, proteomics and transcriptomics. Metabolomics determines the end point of cellular processes and hence defines the readout of the current physiological status of the system. For instance, discoveries related to oncometabolites have highlighted the potential unsuspected cellular pathways, the components of which could serve as diagnosis and prognosis biomarkers or as possible therapeutic targets for disease treatment [14].

Still, very few studies have used metabolomics in the context of EC and most of them have been conducted comparing non-tumour tissue or plasma from control subjects with EEC patients [15–17]. In the present study, for the first time, metabolomic profiling was determined using an LC-MS/MS platform to systematically define specific phenotypic patterns associated with histological types of endometrial cancer. More specifically, the main objective of the present study was to evaluate metabolomic differences between SC and EEC tissues in order to identify potential biomarkers for differential diagnosis and prognosis as well as metabolic molecules and pathways involved in the development and progression of SC. Here, we identified a particular metabolic signature related to SC and delved into the mechanistic basis of ADI1 overexpression as a new potential therapeutic target in endometrial carcinogenesis.

2. Materials and Methods
2.1. Patient Sample Collection
All human samples were from patients diagnosed and treated at the Hospital Universitari Arnau de Vilanova de Lleida (HUAV). Tumour samples are available at IRBLLEIDA Biobank registered in the National Registry of Biobanks of Instituto de Salud Carlos III (B.00682). All samples were collected following the current regulations in the biomedical research law, the Royal Decree of Biobanks RD 1716/2011, the European Regulation 2016/679 and the organic law LOPD-GDD 3/2018 on the protection of personal data. Clinical follow up of all patients was obtained from HUAV Clinical Histories. Duration of follow up was defined as time from diagnosis to last date follow up found in clinical history of each patient. Four criteria were defined depending on the clinical status of each patient in last date follow up: (1) No evidence of disease (NED), (2) alive with disease (AWD), (3) dead of disease other than endometrial cancer (DAD) and (4) dead of endometrial disease (DOD). Presence of recurrence during follow up was also collected.

2.2. Metabolite Extraction
Tissue samples were homogenised in a buffer containing 180 mM KCl, 5 mM 3-[N-morpholino] propanesulfonic acid, 2 mM ethylenediaminetetraacetic acid (EDTA), 1 mM diethylenetriaminepentaacetic acid and 1 mM butylated hydroxytoluene, 10 mg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride, pH 7.3 with a Potter–Eljeveim device (DWK Life Sciences GmbH, Hattenbergstr, Germany) at 4 °C. The protein concentration was measured using the Lowry assay (Bio-Rad Laboratories, München, Germany) with bovine serum albumin used as a standard. In the case of each sample, 100 µg were resuspended in a total of 30 µL of homogenising buffer and vortexed for one minute. In order to extract metabolites from tissue homogenates, 90 µL of ice-cold methanol were added to each sample, and the samples were incubated at −20 °C for 1 h and centrifuged at 12,000 × g for 3 min at room temperature, as described elsewhere [15]. The supernatants were recovered, evaporated using a Speed Vac (Thermo Fisher Scientific, Barcelona, Spain) and resuspended in water containing 0.4% acetic acid.
2.3. Metabolome Analysis

For the metabolomic analysis, an Agilent 1290 LC system coupled to an ESI-Q-TOF MS/MS 6520 instrument (Agilent Technologies, Barcelona, Spain) was used. In all cases, 2 µL of extracted sample were applied onto a reversed-phase column (Zorbax SB-Aq 1.8 µm 2.1 × 50 mm; Agilent Technologies, Barcelona, Spain) equipped with a precolumn (Zorbax-SB-C8 Rapid Resolution Cartridge 2.1 × 30 mm 3.5 µm; Agilent Technologies, Barcelona, Spain) with a column temperature of 60 °C. The flow rate was 0.6 mL/min. Solvent A was composed of water containing 0.2% acetic acid, and solvent B was composed of methanol 0.2% acetic acid. The gradient started at 2% B and increased to 98% B in 13 min and held at 98% B for 6 min. Pot-time was set at 5 min. Data were collected in positive electrospray mode, with the TOF operated in full-scan mode at 50–1600 m/z in an extended dynamic range (2 GHz) using N2 as the nebuliser gas (10 L/min, 350 °C). The capillary voltage was 4000 V, with a scan rate of 1.5 scan/s. The ESI source used a separate nebuliser for the continuous, low-level (10 L/min) introduction of reference mass compounds: 121.050873 and 922.009798 (positive ion mode) and 119.036320 and 966.000725 (negative ion mode), which were used for continuous, online mass calibration.

2.4. Metabolomic Data Analysis and Statistics

Data collection was performed using MassHunter data analysis software (Agilent Technologies, Barcelona, Spain), and the molecular characteristics of the compounds were obtained using MassHunter qualitative analysis software (Agilent Technologies, Barcelona, Spain). The molecular feature extractor (MFE) algorithm (Agilent Technologies, Barcelona, Spain) was used to represent the different ions with their own characteristics. Finally, MassHunter Mass Profiler Professional and Metaboanalyst software [18] were used for unsupervised metabolomics analysis. Only samples with at least two ions were selected. Multiple load states were excluded. Only compounds with common characteristics present in more than 50% of samples of the same condition were considered. Those masses that demonstrated significant differences (t-test, \( p \leq 0.05 \)) were searched for in METLIN Metabolite PCD/PCDL (Agilent Technologies, Barcelona, Spain). The identification of each metabolite was based on an orthogonal approach: identical chromatographic behaviour (RT ± 0.5 min) and identical mass/charge (≤ 30 ppm) in those molecules present in the PCDL database. Furthermore, potential identities were also obtained by searching in the HBMD database [19], considering M + H, M + NH4, M + H-H2O and M + Na adducts. The identity of these metabolites was then confirmed, when possible, by the MS/MS spectrum obtained in different runs.

2.5. Bioinformatic Analysis of Clinical Data

Gene expression data (RSEM), gene mutational data and the related clinical information of TCGA-UCEC [20] patients were downloaded from cbioportal [21,22]. The Wilcoxon rank sum test (wilcox.test R function) was performed to test the difference in terms of expression levels of ADI1 between tumour subtypes and the TP53 mutation status. The Maxstat package [23] was used to determine a cutoff point to stratify patients into ADI1 high-expression and low-expression groups. Kaplan–Meier plots for progression-free survival and overall survival, adjusted to the Cox model of proportional hazards, were used to illustrate the survival curves of ADI1 for the two groups.

2.6. Immunohistochemical Analysis

For the validation of the results of the metabolomic analysis with immunohistochemical techniques, two TMAs were constructed: one with endometrioid carcinomas and one with serous carcinomas. Two areas of each case were selected for TMAs from tumour samples.

TMAs were built with the 3DHistech TMA Grand Master automatic array and its corresponding software 3DHistech TMA Control software (3DHistech Limited, Budapest, Hungary). Each TMA was cut into 3 micron sections and dried at 65 °C. The deparaffinisa-
tion, rehydration and antigen recovery pretreatments were then performed in the PT-LINK pretreatment module (DAKO) at 95 °C for 20 min. with 50 × Tris/EDTA buffer at pH9. Endogenous peroxidase was inhibited before staining the sections.

Acireductone Dioxigenase 1 (ADI1) antibody was used. After incubation, the reaction was visualised with the EnVision Detection Kit (DAKO) using diaminobenzidine as substrate. Sections were counterstained with hematoxylin. Positive and negative controls were tested for each technique. Immunohistochemical assessment was performed by two pathologists using pre-established assessment criteria. Immunoeexpression was graduated semiquantitatively considering the percentage of stained cells and the intensity of the staining. A score or histoscore from 0 (no immunostaining observed) to 300 (maximum immunostaining) was obtained from each of the TMA samples. The histocore of each case was calculated using the following formula: HISTOSCORE = 1 × (% of cells with mild intensity) + 2 × (% of cells with moderate intensity) + 3 × (% of cells with strong intensity).

2.7. Cell Culture

Human endometrioid EC cell HEC-1a and AN3CA, were purchased from the American Type Culture Collection (2008; ATCC-authentication by isoenzymes analysis). Ishikawa 3-H-12 (IK) and MFE-296 cell lines were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Cells were expanded in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich) supplemented with 10% foetal bovine serum (FBS; Invitrogen), 1 mmol/L HEPES (Sigma-Aldrich), 1 mmol/L sodium pyruvate (Sigma-Aldrich), 2 mmol/L L-glutamine (Sigma-Aldrich), 1% penicillin/streptomycin (Sigma-Aldrich) at 37 °C with saturating humidity and 5% CO₂.

2.8. Plasmid Transfection

The lentivirus carrying ADI1 shRNA clones were purchased from Applied Biological Materials Inc. The lentivirus transduction was conducted as previously described [24]. The clone IDs of ADI1 shRNAs used in this study were #i00613a and #i000613b. The target sequences were 5′-GAACTACTCTGGATGGACAT-3′ and 5′-GAGCATTTGCACTTGGACGAT-3′, respectively. Plasmid for ADI1 overexpression (forward sequence 5′-AGTTAAGCTTTATGGTGACAGGTGGTCAGCAT-3′ inserted in pcDNA™3.1/V5-HisB-ADI) were kindly provided by Dr. Chu [25]. Plasmid transfection was performed with Lipofectamine 2000 reagent (Invitrogen Incorporated, Waltman, MA, USA) following the manufacturer’s instructions.

2.9. Wound Healing Assay

Cells were plated in 24-well plates and incubated to almost complete confluence, and a 10 µL pipette tip was then used to scratch the cell layer. The gap widths were imaged in an inverted microscope after scratching (0 h and 24 h) and these were measured using the Image J (NIH LOCI, University of Wisconsin, Madison, WI, USA) program.

2.10. Transwell Invasion Assay

Cells were plated in the upper chamber of the Transwell (8 µm pore, Corning Incorporated, Corning, NY, USA) coated with Matrigel in serum-free medium at a density of 1 × 10⁴ per well. FBS 10% was used as a chemoattractant. After 48 h, cells were fixed with paraformaldehyde 4% and stained with Hoescht (5 µg/mL). Finally, cells were pictured with an epifluorescence microscope (Leica, Wetzlar, Germany), before and after a cotton swab. Results were analysed to obtain the percentage of invasive cells using the software Image J.3 (NIH LOCI, University of Wisconsin, Madison, WI, USA).

3. Results

3.1. Clinical Parameters of Human Samples

To conduct the metabolomic analysis, a total of 31 cases were selected, consisting of 20 samples of endometrial endometrioid carcinoma (EEC) of different histological grades and stages (Table 1) and 11 samples of serous carcinoma (SC) (high histological grade),
previously frozen in liquid nitrogen. For the immunohistochemical study, 96 cases (with 67 being EEC and 29 SC) were selected. All samples were embedded in paraffin blocks. The series of endometrial endometrioid carcinomas consisted of 33 EEC grade I, 23 EEC grade II and 11 EEC grade III carcinomas. The pathological stage of all endometrial endometrioid carcinomas was determined. We identified 55 carcinomas in stage 1, 7 carcinomas in stage 2, 4 carcinomas in stage 3, and 1 in stage 4. The pathological stage of all serous carcinomas was determined and 10 carcinomas in stage 1, 3 carcinomas in stage 2, 9 carcinomas in stage 3 and 7 in stage 4 were identified (Table 2). To obtain good quality with respect to the immunohistochemical analysis, the use of old FFPE tissue samples is not recommended [26–28]. As metabolomics analysis was developed prior to immunohistochemical validation, paired samples were not used for this study.

Table 1. Clinical features of human samples used for metabolomics analysis.

| Case | Age At Diagnosis | Histological Type | Grade | Stage | Molecular Classification | Recurrence | Follow Up | Duration Follow Up (Years) |
|------|-----------------|-------------------|-------|-------|-------------------------|------------|----------|---------------------------|
| 1    | 79              | EEC               | II    | pT3a  | MSI                     | YES        | DOD      | 4                         |
| 2    | 78              | EEC               | I     | pT1a  | LCN                     | NO         | NED      | 4                         |
| 3    | 56              | EEC               | II    | pT1a  | MSI                     | NO         | NED      | 4                         |
| 4    | 69              | EEC               | II    | pT1a  | MSI                     | NO         | NED      | 4                         |
| 5    | 85              | EEC               | II    | pT1a  | LCN                     | NO         | NED      | 4                         |
| 6    | 79              | EEC               | II    | pT1b  | LCN                     | NO         | NED      | 4                         |
| 7    | 76              | EEC               | II    | pT1b  | LCN                     | NO         | NED      | 4                         |
| 8    | 60              | EEC               | I     | pT1b  | LCN                     | NO         | NED      | 4                         |
| 9    | 65              | EEC               | II    | pT3c  | LCN                     | YES        | DOD      | 4                         |
| 10   | 84              | EEC               | III   | pT1b  | LCN                     | NO         | NED      | 3                         |
| 11   | 71              | EEC               | III   | pT1b  | POLE                    | NO         | DAD      | 3                         |
| 12   | 64              | EEC               | I     | pT1a  | LCN                     | NO         | NED      | 3                         |
| 13   | 85              | EEC               | II    | pT1b  | MSI                     | NO         | DAD      | 2                         |
| 14   | 86              | EEC               | I     | pT1b  | MSI                     | NO         | NED      | 5                         |
| 15   | 80              | EEC               | II    | pT1b  | MSI                     | NO         | DAD      | 5                         |
| 16   | 70              | EEC               | I     | pT1a  | MSI                     | NO         | NED      | 6                         |
| 17   | 45              | EEC               | II    | pT1a  | POLE                    | NO         | NED      | 7                         |
| 18   | 39              | EEC               | II    | pT3c  | LCN                     | NO         | NED      | 7                         |
| 19   | 86              | EEC               | I     | pT1a  | LCN                     | NO         | NED      | 7                         |
| 20   | 64              | EEC               | II    | pT1b  | MSI                     | NO         | NED      | 7                         |
| 21   | 81              | SC                | III   | pT3a  | HCN                     | YES        | DOD      | 7                         |
| 22   | 91              | SC                | III   | pT2   | HCN                     | NO         | DAD      | 7                         |
| 23   | 76              | SC                | III   | pT1a  | HCN                     | YES        | DOD      | 5                         |
| 24   | 81              | SC                | III   | pT3b  | HCN                     | YES        | DOD      | 4                         |
| 25   | 58              | SC                | III   | pT3c  | LCN                     | YES        | DOD      | 4                         |
| 26   | 83              | SC                | III   | pT3a  | HCN                     | YES        | DOD      | 4                         |
| 27   | 74              | SC                | III   | pT3b  | HCN                     | YES        | DOD      | 4                         |
| 28   | NA              | SC                | III   | NA    | HCN                     | NA         | NA       | NA                        |
| 29   | NA              | SC                | III   | NA    | HCN                     | NA         | NA       | NA                        |
| 30   | NA              | SC                | III   | NA    | HCN                     | NA         | NA       | NA                        |
| 31   | 76              | SC                | III   | pT3b  | HCN                     | NA         | NA       | NA                        |

Abbreviations: EEC: endometrioid endometrial carcinoma; SC: serous carcinoma; POLE: exonuclease domain of the DNA polymerase epsilon (group 1); MSI: microsatellite instability (group 2); CNL: low copy-number (group 3); CNH: high copy-number or serous-like (group 4); DOD: death of disease; NED: evidence of disease; DAD: dead of another disease; NA: not assessed.

3.2. Characterisation of Metabolomic Differences between SC and EEC

The first aim of this work was to recognise metabolomic differences between SC and EEC. Low molecular weight ionisable molecules (m/z ≤ 3000) were selected for the analysis (5649). In order to define the most reliable and robust metabolites, we selected only those molecules which were present at least in 50% of the samples in any group (1037) and applied multivariate statistics. Principal component analysis (PCA) (Figure 1A) revealed a
differential metabolomics profile in SC and EEC carcinomas, showing that SC samples are more homogenous than EEC samples. These differences were confirmed when hierarchical clustering analysis was applied to the same features (Supplementary File S1). Additionally, when a supervised approach was performed, partial least discriminant analysis (PLS-DA) reinforced the idea of a specific metabolomics signature that can discern between SC and EEC (accuracy: 1, R2: 0.99, Q2: 0.59) (Figure 1B). Figure 1C shows the 15 metabolites that contribute most to define the first component of the PLS-DA, which better discriminates between groups (Figure 1C). All these metabolites, with the exception of the unknown compound 377.7853_11.7, were decreased in SC individuals. Then, with the objective to further describe the metabolomics signature, we selected the 25 lipid species with the lowest p-values, thus obtaining a perfect clusterisation of the samples according to their group (Figure 1D,E). Notably, 23 of the 25 metabolites were down-regulated in SC samples, whereas two of them (adenosine monophosphate and 2′-Deoxyguanosine 5′ monophosphate,) were increased in SC samples (Figure 1F).

Table 2. Clinical features of human samples used for the immunohistochemical study.

| Case | Age at Diagnosis | Histological Type | Grade | Stage | Molecular Classification | Recurrence | Follow Up | Duration Follow Up (Years) |
|------|------------------|-------------------|-------|-------|--------------------------|------------|-----------|--------------------------|
| 1    | 80               | EEC               | II    | IB    | MSI                      | NO         | NED       | 3                       |
| 2    | 59               | EEC               | I     | IA    | LCN                      | NO         | NED       | 4                       |
| 3    | 55               | EEC               | I     | IA    | MSI                      | NO         | NED       | 4                       |
| 4    | 54               | EEC               | III   | IA    | LCN                      | NO         | NED       | 3                       |
| 5    | 62               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 6    | 72               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 7    | 63               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 8    | 54               | EEC               | I     | IA    | MSI                      | NO         | NED       | 3                       |
| 9    | 64               | EEC               | II    | IA    | LCN                      | NO         | NED       | 4                       |
| 10   | 56               | EEC               | I     | IA    | MSI                      | NO         | NED       | 3                       |
| 11   | 60               | EEC               | II    | IA    | MSI                      | NO         | NED       | 3                       |
| 12   | 60               | EEC               | III   | IB    | MSI                      | NO         | NED       | 3                       |
| 13   | 69               | EEC               | I     | IA    | MSI                      | NO         | NED       | 3                       |
| 14   | 66               | EEC               | II    | IIIB  | LCN                      | NO         | NED       | 3                       |
| 15   | 59               | EEC               | I     | IA    | MSI                      | SI         | AWD       | 3                       |
| 16   | 80               | EEC               | I     | IB    | LCN                      | NO         | NED       | 3                       |
| 17   | 78               | EEC               | III   | IIIB  | MSI                      | NO         | NED       | 3                       |
| 18   | 68               | EEC               | II    | IB    | MSI                      | NO         | NED       | 3                       |
| 19   | 50               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 20   | 80               | EEC               | I     | IA    | MSI                      | NO         | NED       | 3                       |
| 21   | 84               | EEC               | I     | IB    | MSI                      | NO         | NED       | 3                       |
| 22   | 61               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 23   | 86               | EEC               | II    | IA    | LCN                      | NO         | NED       | 3                       |
| 24   | 86               | EEC               | I     | II    | MSI                      | NO         | NED       | 3                       |
| 25   | 57               | EEC               | III   | IB    | MSI                      | NO         | NED       | 3                       |
| 26   | 69               | EEC               | I     | IA    | LCN                      | NO         | NED       | 3                       |
| 27   | 69               | EEC               | I     | IA    | POLE                     | NO         | NED       | 3                       |
| 28   | 66               | EEC               | II    | IIIC  | MSI                      | NO         | NED       | 3                       |
| 29   | 63               | EEC               | I     | IA    | MSI                      | NO         | NED       | 2                       |
| 30   | 76               | EEC               | II    | IB    | LCN                      | NO         | NED       | 2                       |
| 31   | 62               | EEC               | I     | IA    | MSI                      | NO         | NED       | 2                       |
| 32   | 64               | EEC               | III   | II    | P53                      | NO         | NED       | 5                       |
| 33   | 53               | EEC               | III   | II    | NA                       | NO         | NED       | 7                       |
| 34   | 70               | EEC               | III   | IB    | POLE                     | NO         | DAD       | 7                       |
| 35   | 83               | EEC               | III   | IB    | LCN                      | NO         | NED       | 7                       |
| 36   | 59               | EEC               | III   | II    | MSI                      | NO         | DAD       | 4                       |
| 37   | 79               | EEC               | II    | IA    | NA                       | NO         | NED       | 5                       |
| 38   | 88               | EEC               | II    | IA    | MSI                      | NO         | DOD       | 5                       |
| Case | Age at Diagnosis | Histological Type | Grade | Stage | Molecular Classification | Recurrence | Follow Up | Duration Follow Up (Years) |
|------|-----------------|-------------------|-------|-------|--------------------------|------------|----------|--------------------------|
| 39   | 80              | EEC               | I     | IB    | NA                       | NO         | DAD      | 5                        |
| 40   | 69              | EEC               | II    | II    | NA                       | NO         | NED      | 7                        |
| 41   | 68              | EEC               | II    | IB    | NA                       | NO         | NED      | 7                        |
| 42   | 64              | EEC               | III   | IB    | MSI                      | NO         | NED      | 7                        |
| 43   | 77              | EEC               | I     | IB    | NA                       | NO         | DAD      | 6                        |
| 44   | 67              | EEC               | II    | IB    | NA                       | SI         | AWD      | 7                        |
| 45   | 67              | EEC               | I     | IB    | MSI                      | NO         | NED      | 7                        |
| 46   | 49              | EEC               | III   | IV    | MSI                      | NO         | DAD      | 7                        |
| 47   | 82              | EEC               | II    | II    | NA                       | NO         | DAD      | 7                        |
| 48   | 82              | EEC               | II    | IB    | NA                       | NO         | NED      | 7                        |
| 49   | 77              | EEC               | II    | IB    | NA                       | NO         | DAD      | 7                        |
| 50   | 75              | EEC               | II    | IB    | NA                       | NO         | NED      | 7                        |
| 51   | 75              | EEC               | II    | IB    | LCN                      | NO         | NED      | 7                        |
| 52   | 62              | EEC               | II    | II    | NA                       | NO         | DAD      | 5                        |
| 53   | 85              | EEC               | I     | IB    | NA                       | NO         | NED      | 8                        |
| 54   | 54              | EEC               | I     | III   | NA                       | NO         | NED      | 8                        |
| 55   | 69              | EEC               | I     | IB    | NA                       | NO         | NED      | 8                        |
| 56   | 80              | EEC               | II    | IB    | NA                       | NO         | DAD      | 5                        |
| 57   | 64              | EEC               | I     | IA    | NA                       | NO         | NED      | 8                        |
| 58   | 47              | EEC               | I     | IA    | NA                       | SI         | DOD      | 7                        |
| 59   | 67              | EEC               | I     | IA    | NA                       | NO         | NED      | 7                        |
| 60   | 46              | EEC               | I     | IA    | LCN                      | NO         | NED      | 7                        |
| 61   | 82              | EEC               | I     | IA    | NA                       | NO         | DAD      | 6                        |
| 62   | 55              | EEC               | II    | IA    | NA                       | NO         | NED      | 7                        |
| 63   | 62              | EEC               | II    | IA    | NA                       | NO         | NED      | 7                        |
| 64   | 63              | EEC               | II    | IA    | NA                       | NO         | NED      | 7                        |
| 65   | 68              | EEC               | II    | IA    | MSI                      | NO         | DAD      | 6                        |
| 66   | 70              | EEC               | I     | IA    | LCN                      | NO         | DAD      | 6                        |
| 67   | 70              | EEC               | I     | IA    | NA                       | NO         | NED      | 7                        |
| 68   | 68              | SC                | III   | IA    | PA3                      | NO         | NED      | 3                        |
| 69   | 75              | SC                | III   | IB    | PA3                      | NO         | NED      | 3                        |
| 70   | 84              | SC                | III   | IB    | LCN                      | NO         | DAD      | 3                        |
| 71   | 59              | SC                | III   | IA    | PA3                      | NO         | NED      | 3                        |
| 72   | 87              | SC                | III   | II    | PA3                      | NO         | DAD      | 3                        |
| 73   | 76              | SC                | III   | IV    | PA3                      | SI         | AWD      | 3                        |
| 74   | 76              | SC                | III   | IIIA  | PA3                      | NA         | NA       | NA                       |
| 75   | 70              | SC                | III   | IV    | PA3                      | SI         | DOD      | 3                        |
| 76   | 73              | SC                | III   | IIIB  | PA3                      | SI         | DOD      | 3                        |
| 77   | 67              | SC                | III   | IA    | PA3                      | NO         | NED      | 2                        |
| 78   | 58              | SC                | III   | IV    | PA3                      | SI         | DOD      | 2                        |
| 79   | 68              | SC                | III   | III C| PA3                      | NO         | NED      | 2                        |
| 80   | 77              | SC                | III   | IA    | PA3                      | NO         | NED      | 2                        |
| 81   | 72              | SC                | III   | IA    | PA3                      | NO         | NED      | 5                        |
| 82   | 55              | SC                | III   | IV    | PA3                      | SI         | DOD      | 5                        |
| 83   | 77              | SC                | III   | IV    | PA3                      | SI         | DOD      | 5                        |
| 84   | 75              | SC                | III   | IIIA  | PA3                      | SI         | DOD      | 4                        |
| 85   | 84              | SC                | III   | IIIA  | PA3                      | SI         | DOD      | 4                        |
| 86   | 75              | SC                | III   | IIIB  | PA3                      | SI         | DOD      | 4                        |
| 87   | 91              | SC                | III   | II    | PA3                      | NO         | DAD      | 4                        |
| 88   | 70              | SC                | III   | IV    | PA3                      | SI         | DOD      | 4                        |
| 89   | 78              | SC                | III   | III C| PA3                      | SI         | DOD      | 4                        |
| 90   | 78              | SC                | III   | IB    | LCN                      | SI         | DOD      | 4                        |
| 91   | 72              | SC                | III   | IIIV  | PA3                      | SI         | DOD      | 4                        |
| 92   | 71              | SC                | III   | IA    | PA3                      | SI         | DOD      | 4                        |
| 93   | 84              | SC                | III   | IV    | PA3                      | SI         | DOD      | 4                        |
Table 2. Cont.

| Case | Age at Diagnosis | Histological Type | Grade | Stage | Molecular Classification | Recurrence | Follow Up | Duration Follow Up (Years) |
|------|------------------|-------------------|-------|-------|--------------------------|------------|----------|---------------------------|
| 94   | 87               | SC                | III   | II    | P53                      | SI         | DOD      | 5                         |
| 95   | 77               | SC                | III   | IIIB  | P53                      | SI         | DOD      | 5                         |
| 96   | 86               | SC                | III   | IB    | P53                      | SI         | DOD      | 5                         |

Abbreviations: EEC: endometrioid endometrial carcinoma; SC: serous carcinoma; POLE: exonuclease domain of the DNA polymerase epsilon (group 1); MSI: microsatellite instability (group 2); CNL: low copy-number (group 3); CNH: high copy-number or serous-like (group 4); DOD: death of disease; NED: evidence of disease; DAD: dead of another disease; AWD: alive with disease; NA: not assessed.

Figure 1. Multivariate statistics using a whole metabolome show a specific signature defining endometrioid and serous carcinomas. (A) Two-dimensional principal component analysis (PCA) representation of features using two principal components. (B) Hierarchical clustering of individual samples according to metabolite levels. (C) Two-dimensional partial least square discriminant analysis (PLS-DA) representation of features using two principal components (accuracy: 1, R²: 0.99, Q²: 0.59). (D) Variable important projection (VIP) scores indicating the elements which contribute most to define the first component of a PLS-DA. (E) Hierarchical clustering of individual samples according to metabolite level using those metabolites with a corrected p-value (FDR) < 0.05. (F) Hierarchical clustering of average sample values according to metabolite level using those metabolites with a corrected p-value (FDR) < 0.05.
samples according to metabolite levels. (C) Two-dimensional partial least square discriminant analysis (PLS-DA) representation of features using two principal components (accuracy: 1, R2: 0.99, Q2: 0.59). (D) Variable important projection (VIP) scores indicating the elements which contribute most to define the first component of a PLS-DA. (E) Hierarchical clustering of individual samples according to metabolite level using those metabolites with a corrected p-value (FDR) < 0.05. F) Hierarchical clustering of average sample values according to metabolite level using those metabolites with a corrected p-value (FDR) < 0.05.

Following multivariate statistics, we focused on defining the specific metabolites that are statistically different from one group to the other (Student t-test, p < 0.05). We found 232 metabolites, 54 of them with a corrected p-value (FDR) < 0.05 (Supplementary File S1). Among the 232, 93 (40%) were identified as belonging to different families based on exact mass, retention time, isotopic distribution and/or MS/MS spectrum (Table 3). In particular, we found 3 (3.2%) benzene and substituted derivative metabolites, 5 (5.43%) carboxylic acids and derivatives, 7 (7.5%) fatty acyls (4 fatty acids and conjugates, 1 eicosanoid, 1 lineolic acid and derivative and 1 fatty acid ester), 15 (16.1%) glycerolipids (6 monoradyl-glycerols and 9 diradylglycerols), 46 (49.4%) glycerophospholipids (19 glycerophosphates, 10 glycerophosphoglycerols, 1 glycerophosphoinositol, 6 glycerophosphocholines, 6 glycerophosphoethanolamines, 2 glycerophosphoserines, 1 glycerophosphoinositolphosphate and 1 CDP-glycerol), 1 (1%) organoxigen compound, 2 (2%) prenol lipids, 1 (1%) purine nucleotide, 10 (10.7%) sphingolipids (all of them sphingomyelins) and 3 (3.2%) steroid and steroid derivatives. Notably, mostly lipid species (96.4%) showed lower levels in SC compared to EEC, while those metabolites that belonged to amino acids and purine nucleotides showed higher levels in SC. The regulation (low or high levels) for all the differential metabolites is shown in the Supplementary File S1.

Table 3. Metabolites statistically different between SC and EEC samples (p < 0.05).

| Class                          | Subclass                      | Compound                  | m/z      | rt  | p Value  | FDR       | Regulation (sc vs. eec) |
|-------------------------------|-------------------------------|---------------------------|----------|-----|----------|-----------|------------------------|
| Benzene and substituted       | Benzoic acids and derivatives | Phthalic acid             | 149.0255 | 9.5 | 0.0096685| 0.09476   | down                   |
| derivatives                   |                               | Dihexyl phthalate         | 363.2476 | 11.5| 0.0041352| 0.059558  | down                   |
|                               |                               | Phthalic acid mono-2-ethylhexyl ester | 279.1545 | 9.5 | 0.003451 | 0.058653 | up                     |
| Carboxylic acids and          | Amino acids, peptides and     | Glutathione               | 308.0837 | 0.4 | 0.040854 | 0.19345   | up                     |
| derivatives                    | analogues                      | L-Isoleucine              | 249.1468 | 0.4 | 0.045153 | 0.20275   | up                     |
|                               |                               | Valine                    | 118.0784 | 0.4 | 0.033932 | 0.17334   | up                     |
|                               |                               | N-Jasmonoylisoleucine     | 324.2122 | 9.5 | 0.045153 | 0.20275   | up                     |
|                               |                               | Leucyl-phenylalanine      | 279.1661 | 9.5 | 0.0065027 | 0.078944 | down                   |
|                               |                               | 2-oxo-4-methylthiobutanoic acid | 149.0165 | 11.9| 0.02082 | 0.13665   | up                     |
| Fatty acids and conjugates    |                               | Tetracosatetraenolic acid | 343.2939 | 7.4 | 0.0009416 | 0.030514 | down                   |
| Fatty acids                   |                               | Eicosatetraenolic acid    | 307.2528 | 11.9| 0.0087278 | 0.090507 | up                     |
|                               |                               | FAHFA(16:0/13-O-16:0)     | 549.4234 | 12.9| 0.010143 | 0.09476   | down                   |
| Eicosanoids                   |                               | 8-iso-15-keto-PGE2        | 373.2053 | 7.4 | 0.010132 | 0.09476   | down                   |
| Lineolic acids and conjugates |                               | alpha-Linolenic acid      | 279.2193 | 11.4| 0.026493 | 0.15008   | down                   |
| Fatty acid esters             |                               | Linoleyl carnitine        | 424.3364 | 9.8 | 0.020487 | 0.13665   | up                     |
| Class                | Subclass            | Compound     | m/z      | rt  | p Value | FDR   | Regulation (sc vs. eec) |
|---------------------|---------------------|--------------|----------|-----|---------|-------|-------------------------|
| **Glycerolipids**   |                     |              |          |     |         |       |                          |
|                     | MG(18:1) b          | 357.293      | 11.3     | 0.013272 | 0.11253 | down |
|                     | MG(18:3) b          | 375.2435     | 10.4     | 0.0056723 | 0.070026 | down |
|                     | MG(20:5) b          | 399.2496     | 11.7     | 0.006547 | 0.078944 | down |
|                     | MG(22:0) b          | 453.3387     | 5.9      | 0.011262 | 0.1022  | down |
|                     | MG(i-17:0) b        | 367.2718     | 11.4     | 0.026493 | 0.15008 | down |
|                     | DG(34:4) b          | 589.4824     | 13.2     | 0.0064951 | 0.021727 | down |
|                     | DG(36:6) b          | 613.4706     | 13.1     | 0.013272 | 0.11253 | down |
|                     | DG(34:11) b         | 737.4961     | 10.9     | 0.03685 | 0.17334 | down |
|                     | DG(37:6) b          | 627.4929     | 13.2     | 0.025968 | 0.15008 | down |
|                     | DG(36:5) b          | 615.4996     | 13.2     | 0.017212 | 0.12309 | down |
|                     | DG(i-28:0) b        | 535.4314     | 12.9     | 0.0056723 | 0.070026 | down |
|                     | Glycerophospholipids|              |          |     |         |       |                          |
|                     | LysoPA(18:1) b      | 419.2675     | 10.5     | 0.0000217 | 0.0037419 | down |
|                     | LysoPA(P-16:0) b    | 377.2554     | 10.9     | 0.044511 | 0.20275 | down |
|                     | LysoPA(20:3) b      | 499.2271     | 6.9      | 0.013508 | 0.11253 | down |
|                     | LysoPA(22:1) b      | 475.32       | 8.2      | 0.0041352 | 0.059558 | down |
|                     | LysoPA(20:2) b      | 463.2957     | 10.6     | 0.0027798 | 0.012533 | down |
|                     | PA(P-34:2) b        | 657.503      | 13       | 0.02976 | 0.16074 | down |
|                     | PA(36:6) b          | 693.4684     | 10.8     | 0.0056723 | 0.070026 | down |
|                     | PA(28:1) b          | 573.4021     | 12.6     | 0.025604 | 0.15008 | down |
|                     | PA(29:1) b          | 605.4157     | 10.7     | 0.0021604 | 0.042052 | down |
|                     | PA(30:2) b          | 617.4202     | 10.8     | 0.00015155 | 0.0098224 | down |
|                     | PA(40:7) b          | 747.4967     | 12.5     | 0.021704 | 0.13943 | up    |
|                     | PA(36:7) b          | 691.4537     | 10.5     | 0.0037003 | 0.059558 | down |
|                     | PA(38:5) b          | 705.4727     | 10.9     | 0.0076209 | 0.084073 | down |
|                     | PA(44:9) b          | 781.5218     | 10.9     | 0.019748 | 0.13665 | down |
|                     | PA(48:0) b          | 855.7351     | 14.9     | 0.0000866 | 0.0081641 | down |
|                     | PA(46:7) b          | 831.5771     | 12.2     | 0.0076209 | 0.084073 | down |
|                     | PA(48:2) b          | 891.6926     | 14.3     | 0.0098617 | 0.09476  | down |
|                     | PA(48:1) b          | 853.4021     | 14.6     | 0.0061506 | 0.078944 | down |
|                     | PA(48:2) b          | 891.4932     | 13.2     | 0.0064951 | 0.021727 | down |
|                     | PA(42:9) b          | 747.3584     | 12.5     | 0.021704 | 0.13943 | up    |
|                     | LysoPI(18:1) b      | 493.3069     | 10.2     | 0.0000217 | 0.0037419 | down |
|                     | LysoPC(40:5) b      | 825.5433     | 10.9     | 0.0028977 | 0.052513 | down |
|                     | LysoPC(40:9) b      | 801.4891     | 10.6     | 0.0000217 | 0.0037419 | down |
|                     | Glycerophosphoglycerol |              |          |     |         |       |                          |
|                     | PGP(i-30:0) b       | 757.4626     | 10.6     | 0.0000433 | 0.0064146 | down |
|                     | PGP(i-37:0) b       | 873.5459     | 11.2     | 0.033685 | 0.17334 | down |
|                     | PGP(38:7) b         | 793.5243     | 11       | 0.022018 | 0.13943 | down |
|                     | PGP(i-30:2) b       | 713.4383     | 10.5     | 0.0000217 | 0.0037419 | down |
|                     | PGP(i-28:0) b       | 649.4432     | 10.9     | 0.0005173 | 0.024158 | down |
|                     | PGP(42:9) b         | 845.5149     | 10.7     | 0.0012528 | 0.03453 | down |
|                     | PGP(i-27-0) b       | 561.3887     | 10.7     | 0.0097426 | 0.030615 | down |
|                     | LysoPC(18:1) b      | 493.3069     | 10.2     | 0.0000217 | 0.0037419 | down |
|                     | PC(34:5) b          | 752.5083     | 10.6     | 0.0041352 | 0.059558 | down |
|                     | PC(38:6) b          | 806.5721     | 13.5     | 0.035678 | 0.17618 | down |
| Class               | Subclass                        | Compound                  | m/z      | rt | p Value      | FDR       | Regulation (sc vs. eec) |
|---------------------|---------------------------------|---------------------------|----------|----|--------------|-----------|------------------------|
| Glycerophos         | phoethanolamines                | LysoPE(24:1) b            | 546.392  | 10.7| 0.010132    | 0.09476   | down                   |
|                     |                                 | LysoPE(O-16:3) a          | 434.252  | 10.7| 0.017016    | 0.12309   | down                   |
|                     |                                 | PE(O-35:6) a              | 708.481  | 10.5| 0.0021001   | 0.042052  | down                   |
|                     |                                 | PE(38:1) a                | 774.6007 | 13.7| 0.0035067   | 0.058653  | down                   |
|                     |                                 | PE(36:1) a                | 746.5744 | 13.5| 0.0044838   | 0.062834  | down                   |
|                     |                                 | PE(42:9) b                | 796.534  | 10.6| 0.01991     | 0.13665   | down                   |
|                     |                                 | PS(38:3) b                | 814.5753 | 9.5 | 0.0028304   | 0.052435  | down                   |
|                     |                                 | PS(40:1) b                | 884.5858 | 10.7| 0.049943    | 0.22133   | down                   |
|                     | phoserines                      | LysoPE(O-16:3)            | 434.252  | 10.7| 0.017016    | 0.12309   | down                   |
|                     |                                 | LysoPE(O-35:6)            | 708.481  | 10.5| 0.0021001   | 0.042052  | down                   |
|                     |                                 | LysoPE(38:1) a            | 774.6007 | 13.7| 0.0035067   | 0.058653  | down                   |
|                     |                                 | LysoPE(36:1) a            | 746.5744 | 13.5| 0.0044838   | 0.062834  | down                   |
|                     |                                 | LysoPE(42:9) b            | 796.534  | 10.6| 0.01991     | 0.13665   | down                   |
|                     |                                 | LysoPE(38:3) b            | 814.5753 | 9.5 | 0.0028304   | 0.052435  | down                   |
|                     |                                 | LysoPE(40:1) b            | 884.5858 | 10.7| 0.049943    | 0.22133   | down                   |
| Glycerophos         | phoinositol phosphates          | LysoPE(O-16:3)            | 434.252  | 10.7| 0.017016    | 0.12309   | down                   |
|                     |                                 | LysoPE(O-35:6)            | 708.481  | 10.5| 0.0021001   | 0.042052  | down                   |
|                     |                                 | LysoPE(38:1) a            | 774.6007 | 13.7| 0.0035067   | 0.058653  | down                   |
|                     |                                 | LysoPE(36:1) a            | 746.5744 | 13.5| 0.0044838   | 0.062834  | down                   |
|                     |                                 | LysoPE(42:9) b            | 796.534  | 10.6| 0.01991     | 0.13665   | down                   |
|                     |                                 | LysoPE(38:3) b            | 814.5753 | 9.5 | 0.0028304   | 0.052435  | down                   |
|                     |                                 | LysoPE(40:1) b            | 884.5858 | 10.7| 0.049943    | 0.22133   | down                   |

All compounds are putatively annotated compounds based upon physicochemical properties and/or spectral similarity with public/commercial spectral libraries [29]. (a) Identity (ID) based on exact mass, retention time (RT) and MS/MS spectrum (high reliability); (b) ID based on exact mass and RT.

Globally, the characterisation of the metabolomic differences between EEC and SC showed a differential profile between these two histological subtypes defining a particular signature associated with specific metabolites. Among the identified metabolites, we found several lipids but also different non-lipid species with a potential role in the molecular characterisation of endometrial endometrioid carcinomas and serous carcinomas. We focused our attention on those metabolites up-regulated in SC because of its major aggressiveness and searched for specific antibodies to analyse the affectation of related enzymes.

### 3.3. ADI1 Is Overexpressed in SC Patients

In an attempt to further characterise and validate the metabolomic results obtained, we searched for available antibodies targeting specific enzymes. First, we were struck by the increased levels of two branched-chain amino acids (BCAAs) (valine and isoleucine) of the valine-leucine-isoleucine metabolism pathway in the SC tumours. Therefore, we decided to evaluate the involvement of this pathway in EC tumours.

BCAA aminotransferase 1 (BCAT1) is the enzyme responsible for the synthesis and degradation of valine and leucine. In addition, BCAT1 is also involved in other pathways.
such as “cysteine and methionine metabolism”. To explore the role of this enzyme, an immunohistochemical evaluation of BCAT1 protein was performed. Unfortunately, the results obtained did not show significant differences when comparing protein expression levels in EEC and SC (data not shown).

Another metabolite identified as up-regulated in SC tumours was 2-Oxo-4-methylthiobutanoic acid. 2-Oxo-4-methylthiobutanoic acid is also related to “cysteine and methionine metabolism”, as it is a precursor of L-methionine, synthesised by acyldiaryldioxynogenase 1 (ADI1 or also called Sip-L and MTCBP1). Therefore, we assessed ADI1 protein expression by immunohistochemistry in three independent TMAs. Consistent with previous metabolomics results, we observed a significant overexpression of ADI1 in SC samples compared to EEC samples (Figure 2A) (no differences were found in terms of grade and stage of patients at diagnosis). Next, we analysed the ADI1 mRNA levels from the publicly available TCGA_UCEC database which contains a large cohort of data from endometrial cancer patients [22]. Remarkably, we found that ADI1 mRNA expression levels were enriched in SC patients compared to EEC patients (Figure 2B). All these results reinforced the metabolomics data obtained before.

Figure 2. ADI1 expression and progression-free survival (PFS) of endometrial cancer patients. (A) Immunohistochemistry (IHC) analysis of ADI1 expression levels in EEC and SC samples. (Left) Representative images. Magnification 20× and 100×. (Right) Quantification graph. Graph value is the mean, and error bars are represented as mean ± S.E.M. Statistical analysis was performed using two-tailed paired Student t-test analysis. ** p < 0.01. (B) ADI1 mRNA expression levels in EEC and SC patients. (C) Kaplan–Meier plots of PFS of SC patients, stratified into ADI1 high-expression and low-expression groups. (D) Kaplan–Meier plots of PFS of EEC patients, stratified into ADI1 high-expression and low-expression groups.
expression and low-expression groups. (E) ADI1 mRNA levels of EC patients stratified according to TP53 mutation status. (F) ADI1 mRNA levels of EEC samples stratified according to TP53 mutation status. Gene expression data, gene mutational data and their related clinical information were obtained from TCGA-UCEC public database [20].

Given the observed increased ADI1 levels in SC patients compared to EEC patients, we decided to determine progression-free survival (PFS) rates in SC and EEC patients expressing high levels or low levels of ADI1. Log-rank analysis for PFS from a cohort including 130 patients diagnosed with SC showed a remarkable (although not statistically significant) tendency toward a negative correlation between high ADI expression levels and PFS (p-value = 0.06) rates (Figure 2C). Surprisingly, when analysing this correlation in a cohort of 396 EEC patients, we noticed that the PFS parameter presented a statistically significant correlation with high ADI expression levels (p-value = 0.01) (Figure 2D).

3.4. High ADI1 mRNA Levels Are Associated with Altered P53 Expression

P53 is a tumour suppressor gene altered in ECs, which has been shown to be an independent indicator of poor prognosis [29]. Serous carcinomas are high grade tumours with bad prognosis and usually show altered p53 expression. However, it is also well known that some EECs can also present an altered expression of p53 [30]. This group of tumours are usually high-grade carcinomas and have bad behaviour. Thus, p53 expression has been frequently used as a surrogate marker in SC and EEC [8]. Therefore, we used the TCGA_UCEC database to analyse the association between ADI1 and P53 mutant expression in endometrial carcinomas. Interestingly, as shown in Figure 2E, we found a significant increased expression of ADI1 among those ECs with mutant P53 expression. Next, we further explored the association of ADI1 overexpression and P53 mutant status in EEC. In concordance with previous analyses, mutant p53 EEC also displayed significantly elevated mRNA levels of ADI compared to wildtype P53 expression in EEC (Figure 2F).

3.5. Alteration of ADI1 Expression Modulates Migration and Invasion Capabilities of EEC Cell Lines through Regulation of Epithelial–Mesenchymal Transition Process

In an attempt to investigate the role of ADI1 in the acquisition of an aggressive phenotype in EEC, we performed a western blot assay to assess the levels of ADI1 in four EEC cell lines (Figure 3A). The results obtained showed that differentiated EC cell lines express moderately low levels of ADI1, whereas the dedifferentiated MFE-296 cell lines express high ADI1 protein levels.

Next, we transfected ADI1 over-expression vectors into a HEC-1A cell line and it infected with lentiviral shRNA-ADI1 plasmids MFE-296 cells in order to analyse the functions of ADI1 (Figure 3B). Notably, by performing wound healing and transwell invasion assays, we found that the overexpression of ADI1 in HEC-1A cells significantly enhances the migratory and invasive capacities of these cells (Figure 3C,D). Conversely, lentivirus-mediated ADI1 downregulation led to the opposite effect in MFE-296 cells in terms of migratory and invasive competencies (Figure 3E,F).

It is well known that epithelial–mesenchymal transition (EMT) changes are central processes in the migration and invasion phenomena of endometrial neoplastic cells [31]. Therefore, on the basis of the evidence observed, we next assessed the expression of several epithelial and mesenchymal markers on the ADI1 modulated-expression cell lines by immunofluorescence and western blot assays. Thus, the results obtained show that in the HEC-1A cell line over-expressing ADI1 presented a down-expression of epithelial protein markers such as E-cadherin and β-catenin and an up-regulation of the mesenchymal protein marker vimentin and the EMT transcriptional factor Snail (Figure 4A,B). On the other hand, ADI1 knockdown MFE-296 cells presented a raised expression of E-cadherin and β-catenin epithelial markers and down-regulated protein levels of vimetin and Snail (Figure 4C,D).
Figure 3. Ectopic modification of ADI1 levels modulates migration and invasion capabilities of EEC cell lines. (A) Representative images of western blot analysis of ADI1 levels of Ishikawa (IK), HEC-1A, AN3CA and MFE-296 cells. GAPDH was used as a loading control. (B) Representative images of western blot analysis of ADI1 levels (left) on HEC-1A cell line transfected with ADI1 over-expression vector and (right) MFE-296 cells infected with lentiviral shRNA-ADI1 (shRNA1 ADI1 and shRNA2 ADI1) plasmids. GAPDH was used as a loading control. (C) Representative images at time markers 0 and 24 h after scratch of wound-healing assay performed in HEC-1A cells transfected with ADI1 over-expression vector (left) and quantification of wound closure area between the indicated times (Right). (D) Representative images of nuclear Hoechst staining of transwell invasion assay after the cotton swab in MFE-296 cells infected with lentiviruses carrying shRNA against ADI1 (shRNA1 ADI1 and shRNA2 ADI1) (top panel) and quantification of wound closure area between the indicated times (bottom plot). (F) Representative images of nuclear Hoechst staining of transwell invasion assay after the cotton swab in MFE-296 cells infected with lentiviruses carrying shRNA against ADI1 (shRNA1 ADI1 and shRNA2 ADI1) (upper panel) and quantification of Matrigel invasive cells (bottom plot). Scale bars: 50 μm. Graph values are the mean ± S.E.M. Statistical analysis was performed using one-way ANOVA analysis followed by the Tukey’s multiple comparison test or by two-tailed paired Student t-test analysis. ** p < 0.01; *** p < 0.001. Results shown are representative of at least three independent experiments with a minimum of three technical replicates per experiment. The whole western blots were shown in File S2.
It is well known that epithelial–mesenchymal transition (EMT) changes are central processes in the migration and invasion phenomena of endometrial neoplastic cells [31]. Therefore, on the basis of the evidence observed, we next assessed the expression of several epithelial and mesenchymal markers on the ADI1 modulated expression cell lines by immunofluorescence and western blot assays. Thus, the results obtained show that in the HEC-1A cell line over-expressing ADI1 presented a down-expression of epithelial protein markers such as E-cadherin and β-catenin and an up-regulation of the mesenchymal protein marker vimentin and the EMT transcriptional factor Snail (Figure 4A,B). On the other hand, ADI1 knockdown MFE-296 cells presented a raised expression of E-cadherin and β-catenin epithelial markers and down-regulated protein levels of vimentin and Snail (Figure 4C,D).

Figure 4. Ectopic modification of ADI1 levels modulates epithelial features. (A) Representative images of immunofluorescence against E-cadherin and vimentin in HEC-1A cells transfected with ADI1 over-expression vector. Magnification images of framed regions of the samples are shown. Scale bars: 20 µm. (B) Representative images of western blot analysis of E-cadherin, β-catenin, vimentin and SNAIL in HEC-1A cell line transfected with ADI1 over-expression vector. GAPDH was used as a loading control. (C) Representative images of immunofluorescence against E-cadherin and vimentin in MFE-296 cells infected with lentiviral shRNA1 ADI1 and shRNA2 ADI1 plasmids. Magnification images of framed regions of the samples are shown. Scale bars: 20 µm. (D) Representative images of western blot analysis of E-cadherin, β-catenin, vimentin and SNAIL in MFE-296 cells infected with lentiviral shRNA1 ADI1 and shRNA2 ADI1 plasmids. GAPDH was used as a loading control. The whole western blots were shown in File S2.

4. Discussion

Uterine serous carcinomas are still considered a relatively rare tumour that accounts for about 10% of all ECs, although 40% deaths in EC cases are attributed to this EC subtype [8]. SC, by definition, is regarded as a high-grade tumour and has a high tendency to develop...
lymph node metastasis as well as adnexal and peritoneal spread, even in cases where the primary tumour is small [32]. The terminology “high-risk EC” has been adopted to include SC, clear cell carcinoma and grade 3 EEC due to the poor prognosis associated with these types of tumours. These tumours present low-rate mutations, but the p53 mutation could explain the poor prognosis observed, since the altered expression of p53 has been clearly documented to result in a high degree of genomic instability and fast tumour progression and invasion [33]. A number of previous metabolomics studies have been aimed at defining diagnosis, prognosis and predictive markers of EC. Two recent reviews, references [34,35], systematically summarise these findings. Until now, however, nothing was known about the metabolic differences between EEC and SC EC subtypes. The results presented in the present study suggest that some metabolic pathways are regulated differently depending on the type of EC tumour.

A relevant observation of the present study is that among the differential and identified metabolites that we have reported, 89.2% (83) are lipid species (most of them previously defined as bioactive lipid molecules), suggesting the important role of lipid metabolism in the phenotypic differences between SC and ECC. Remarkably, 96.4% of these lipid species showed lower levels in SC compared to EEC. Among the lipid species with increased levels in SC, the presence of two bile acids is noteworthy. It is well known that bile acids, which are also bioactive lipids, regulate different nuclear receptors including HIF-1alpha [36].

Within the lipid species with decreased levels in SC, we detected signalling molecules such as fatty acids and conjugates, eicosanoids, monoacylglycerols, diacylglycerols (DAG), lyosphosphatidic acids, phosphatidic acids (PA), phosphatidylinositolosolosits (PI) and derivatives as well as one bile acid. The other identified lipid species are essentially structural components of the lipid bilayer and substrates for bioactive lipid species (phosphatidylincholines, phosphatidylethanolamines and sphingomyelins). These bioactive lipids participate in the regulation of a broad spectrum of cellular processes such as inflammation and cell differentiation, growth, proliferation and survival, which are key in the biology of cancer. Particularly striking is the number of lipid species (31) belonging to the PI-DAG-PA signalling axis. DAG has unique functions as a basic component of membranes, an intermediate in lipid metabolism and a key element in lipid-mediated signalling, essential processes for cell homeostasis and survival, and its levels are strictly regulated [37]. Basically, DAGs are generated by the phospholipase C (PLC)-mediated hydrolysis of PI(4,5)P2 (phosphatidylinositol 4,5-bisphosphate), which is also the substrate for PI3K (phosphatidylinositol 3 kinase) activity. DAGs are phosphorylated in a reaction catalysed by diacylglycerol kinases (DGKs) to generate PA, which is the first step in a series of reactions that replenish PI(4,5)P2 levels in the PI cycle. Other DAG sources include the pool generated by phosphatidic acid phosphatases (PAPs) acting on the PA generated by the phospholipase D (PLD)-catalysed hydrolysis of PC (phosphatidylcholine) or that originate from ceramide and PC by the action of sphingomyelinas (SMS) [38]. In cells, DAG, PA and PI(4,5)P2, as lipid second messengers, play an important role in regulating several signal transduction proteins [39] that, in turn, are linked to the regulation of a broad diversity of functions, including the activation of protein kinases, the activation of ion channels and cytoskeletal reorganisation, among several others [38–40], which can promote endometrial cancer progression. In this context, the lower levels of these lipid signalling species could be counterintuitive with respect to their role in cell physiology and the cellular traits expressed by SC tissue. So, it is hypothesised that the lower content of these lipid species expresses a high consumption by the enzymes involved in their signalling pathways in order to sustain cell processes in SC cancer cells. Consistent with this, the high levels observed for specific amino acids as well as nucleotides in SC would indicate the high demands of protein biosynthesis and genetic material necessary to ensure the survival, growth, proliferation and invasion of cancer cells into SC tissue and would reinforce these insights when it comes to lipids. Further studies are needed, however, in order to consolidate these new insights.

In addition to lipids, we also documented a higher level of two BCAAs, valine and isoleucine, comparing SC to EEC. BCAAs are essential amino acids that are involved in
protein biosynthesis, but they also have other functions; BCAA metabolism has recently been proposed as an oncogenic metabolic pathway involved in metabolic reprogramming and cancer progression in several human cancers such as breast cancer and ovarian cancer via various mechanisms including mTOR signalling, ROS homeostasis and the response to hypoxia [41]. In endometrial tumorigenesis, a previous study has shown that high levels of BCAAs and intermediates from BCAA pathways are associated with EC tumour aggressiveness and recurrence [42,43]. Furthermore, prior studies described different metabolites belonging to cysteine and the methionine metabolism as potential biomarkers for the diagnosis and prognosis of EC [44]. In this regard, we reported that 2-oxo-4-methylthiobutanoic, a metabolite of this pathway, was increased in SC.

After analysing the results obtained through the application of high throughput metabolomics techniques, we also analysed the protein expression levels of the ADI1 enzyme. Our results showed that both SC and EEC with the mutant expression of p53 presented an increased expression of ADI1. The conserved role of ADI1 has been described and classified as an ARD/ARD′ (acireductone dioxygenase) member protein [45]. As an acireductone dioxygenase, ADI1 participates in the methionine salvage pathway or the 5′-methylthioadenosine (MTA) cycle and needs Fe²⁺ as a cofactor to achieve its function in the production of 2-oxo-4-methylthiobutanoic acid, a key step in this pathway [25]. In addition to serving as a key enzyme in the MTA cycle, the role of ADI1 in carcinogenesis is very controversial. On the one hand, ADI1 has been described as a potential tumour suppressor in hepatocellular carcinoma and prostate tumours [25,46,47]. On the other hand, increased ADI1 expression has been described in glioblastoma tumours and implicated in the acquisition of cellular migration capacity [48]. Although expressed in the uterus [49], the function of ADI1 and its involvement in endometrial carcinogenesis remain elusive. Here, we demonstrated how ADI1 is overexpressed in SC and mutant p53 EEC, and its increased expression results in a poor outcome for EEC patients. This could be explained by the alterations in migratory and invasive capabilities that determine the overexpression of ADI1 in endometrial carcinoma cells. While it is appealing to assume that the upregulation of ADI1 and its ability to induce EMT and malignant transformation in EC cells could be a consequence of p53 modified expression, as some studies have suggested [50,51], the molecular mechanism by which ADI1 induces the observed malignant transformation is unknown. One proposed model suggests that ADI1 may also play a role in the phosphorylation of casein kinase II protein (CK2), since three potential CK2 phosphorylation sites (ser10, Ser6 and Thr136) have been described [52]. This hypothesis could explain the observed results, as increased CK2 activity has been associated with cell proliferation and anchorage-independent growth in endometrial cancer cells [53]. Another explanation is that ADI1 abrogates MT1-MMP (membrane type-1 matrix metalloproteinase) signalling that triggers autophagy [48,54]. Thus, an unregulated autophagy process may enable EC cells to escape from cell death and may help them develop adaptive mechanisms to survive. Partial or complete EMT has been associated with the invasive phenotype in ECs [31], as the EMT process allows cells to move away from their epithelial cell community and to integrate into the surrounding tissue, even at remote locations. The results presented here show that cells over-expressing ADI1 show a decrease in epithelial protein markers and an increase in mesenchymal proteins. Moreover, these changes endow ADI1-upregulated cells with migratory and invasion capabilities, encompassing the invasive growth mode of the primary tumour and shifting it into a biologically aggressive state that leads to poor outcomes for EC patients.

5. Conclusions

The changes in metabolism observed in tumour cells suggest that the study of metabolomes in cancer tissue provides useful information to characterise both EEC and SC. Our metabolomic approach found that SC cancer cells showed lower levels of lipid signalling species compared to EEC cells, along with an increased content of specific amino acids and nucleotides, suggesting intensive protein and nucleotide biosynthesis as well as the activation of lipid-
mediated signalling pathways likely to ensure the survival, growth, proliferation and invasion of cancer cells that characterise endometrial serous carcinomas. Furthermore, the present study provides evidence that ADI1 overexpression is associated with SC and mutant p53 EEC tumours and its increased expression confers poor outcomes in EEC patients. In this respect, further prospective studies or trials focusing on ADI1 expression in SC and p53 mutant EEC are needed to determine its potential value as a new therapeutic target in endometrial carcinogenesis.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/cancers14122842/s1, File S1: Hierarchical Clustering Analysis of EEC and SC samples; File S2: The whole western blots.

**Author Contributions:** Study conception and design: S.G., M.J., I.P., R.P., X.M.-G. and N.E.; acquisition and interpretation of data: S.G., M.J., I.P., C.M.-L., M.A.-V., A.Y., N.B., D.L.-N., R.P., X.M.-G. and N.E.; bioinformatics analysis: M.J., I.P. and D.L.-N.; optimised conditions for the IHC and histopathology analysis: M.S., S.G. and M.P. All authors participated in the writing of the manuscript and gave their final approval to the submitted version. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by the Instituto de Salud Carlos III (ISCIII) through projects PI20/00502, CP19/00025, CB16/12/00231, PI16/00692, PI18/00573, PI21/00672, CP17/00063 and PI18/00795; and by the Spanish Ministry of Science, Innovation and Universities (Ministerio de Ciencia, Innovación y Universidades, RTI2018-099200-BI00), co-funded by the European Regional Development Fund (ERDF) as part of the “A way to make Europe” programme and the European Social Fund (ESF) as part of the “Investing in Your Future” programme. This study was also supported by the “Xarxa de Bancs de Tumors de Catalunya” and sponsored by “Pla Director d’Oncologia de Catalunya (XBTC)”, “IRBLleida Biobank” (B.000682) and “Plataforma Biobancos” PT20/00021. We also thank the Generalitat of Catalonia: Agency for Management of University and Research Grants (2017SGR1368 and 2017SGR696) and the “Asociación Española Contra el Cáncer” (AECC; Grupos Estables 2018 and LABAE19004LLOB). M.J. is a Serra Húnter Fellow. N.E. (MS19/00025) and D.L.-N. (MS17/00063) are recipients of a Miguel Servet research scheme (co-funded by the ESF program “Investing in Your Future”). C. M-L. holds a predoctoral fellowship from the Generalitat de Catalunya (2020FI_B2 00099) and the predoctoral fellowship “Ajuts 2021 de Promoció de la Recerca en Salut-9ª edició” from IRBLleida/Diputació de Lleida. IRBLleida is a CERCA Program/Generalitat of Catalonia.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of CEIm—Hospital Universitari Arnau de Vilanova (protocol code 1858/minutes 12/2017 approved on 30 November 2017).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets analysed during the current study are available from the corresponding author upon reasonable request.

**Acknowledgments:** The authors want to thank Yu-De Chu (Linkou Chang Gung Memorial Hospital) for providing us with ADI1 overexpression plasmid. The authors also want to thank the Cell Culture Scientific and Technical Service at Universitat de Lleida as well as the Biobank Scientific and Technical Service and the Lipidomics Scientific and Technical Service at IRBLleida.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA A Cancer J. Clin.* 2021, 71, 209–249. [CrossRef] [PubMed]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. *CA A Cancer J. Clin.* 2019, 69, 7–34. [CrossRef] [PubMed]
3. Amant, F.; Moerman, P.; Neven, P.; Timmerman, D.; Van Limbergen, E.; Vergote, I. Endometrial cancer. *Lancet* 2005, 366, 491–505. [CrossRef]
4. Eritja, N.; Chen, B.J.; Rodriguez-Barrueco, R.; Santacana, M.; Gatius, S.; Vidal, A.; Martí, M.D.; Ponce, J.; Bergada, L.; Yeramian, A.; et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017, 13, 608–624. [CrossRef] [PubMed]

5. Fleming, G.F. Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J. Clin. Oncol. 2007, 25, 2983–2990. [CrossRef] [PubMed]

6. Sherman, M.E. Theories of endometrial carcinogenesis: A multidisciplinary approach. Mod. Pathol. 2000, 13, 295–308. [CrossRef]

7. Azueta, A.; Gatius, S.; Matias-Guiu, X. Endometrioid carcinoma of the endometrium: Pathologic and molecular features. Semin. Diagn. Pathol. 2010, 27, 226–240. [CrossRef]

8. Gatius, S.; Matias-Guiu, X. Practical issues in the diagnosis of serous carcinoma of the endometrium. Mod. Pathol. 2016, 29 (Suppl. S1), S45–S58. [CrossRef]

9. Kandoth, C.; Schultz, N.; Cherniack, A.D.; Akbani, R.; Liu, Y.; Shen, H.; Benz, C.C.; Yau, C.; Laird, P.W.; Ding, L.; et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497, 67–73.

10. Puilats, J.M.; Guerra, E.; Gil-Martin, M.; Roman-Canal, B.; Gatius, S.; Sanz-Pamplona, R.; Velasco, A.; Vidal, A.; Matias-Guiu, X. Molecular approaches for classifying endometrial carcinoma. Gynecol. Oncol. 2017, 145, 200–207. [CrossRef]

11. Singh, N.; Hirschowitz, L.; Zaino, R.; Alvarado-Cabrero, I.; Duggan, M.A.; Ali-Fehmi, R.; Euscher, E.; Hecht, J.L.; Horn, L.-C.; Ioffe, O.; et al. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade). Int. J. Gynecol. Pathol. 2019, 38 (Suppl. S1), S93–S113. [CrossRef] [PubMed]

12. Altmäe, S.; Esteban, F.J.; Stavreus-Evers, A.; Simon, C.; Giudice, L.; Lessey, B.A.; Horcajadas, J.A.; Macklon, N.S.; D’Hooghe, T.; Campoy, C.; et al. Guidelines for the design, analysis and interpretation of ‘omics’ data: Focus on human endometrium. Hum. Reprod. Update 2014, 20, 12–28. [CrossRef] [PubMed]

13. Day, R.S.; McDade, K.K.; Chandran, U.R.; Lisovich, A.; Conrads, T.P.; Hood, B.L.; Kolli, V.K.; Kirchner, D.; Litzi, T.; Maxwell, G.L. Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinform. 2011, 12, 213. [CrossRef] [PubMed]

14. Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. Nat. Rev. Drug Discov. 2016, 15, 473–484. [CrossRef] [PubMed]

15. Jové, M.; Gatius, S.; Yeramian, A.; Portero-Otin, M.; Eritja, N.; Santacana, M.; Colas, E.; Ruiz, M.; Pamplona, R.; Matias-Guiu, X. Metabotyping human endometrial endometrioid adenocarcinoma reveals an implication of endocannabinoid metabolism. Oncotarget 2016, 7, 52364–52374. [CrossRef] [PubMed]

16. Altadill, T.; Dowdy, T.M.; Gill, K.; Reques, A.; Menon, S.S.; Moiola, C.P.; Lopez-Gil, C.; Coll, E.; Matias-Guiu, X.; Cabrera, S.; et al. Metabolic and Lipidomic Profiling Identifies the Role of the RNA Editing Pathway in Endometrial Carcinogenesis. Sci. Rep. 2017, 7, 8803. [CrossRef] [PubMed]

17. Troulis, S.; Lee, P.; Pinato, D.J.; Ellis, J.K.; Dina, R.; Aboagye, E.O.; Keun, H.C.; Sharma, R. Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway. Cancer Res. 2014, 74, 6867–6877. [CrossRef]

18. Chong, J.; Wishart, D.S.; Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis. Curr. Protoc. Bioinform. 2019, 68, e86. [CrossRef]

19. Wishart, D.S.; Feunang, Y.D.; Marcu, A.; Guo, A.C.; Liang, K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N.; et al. HMDB 4.0: The human metabolome database for 2018. Nucleic Acids Res. 2018, 46, D608–D617. [CrossRef]

20. Hoadley, K.A.; Yau, C.; Hinoue, T.; Wolf, D.M.; Lazar, A.J.; Drill, E.; Shen, R.; Ponce, J.; Bergada, L.; Yeramian, A.; et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy 2017, 13, 608–624. [CrossRef] [PubMed]
27. Ramos-Vara, J.A.; Webster, J.D.; DuSold, D.; Miller, M.A. Immunohistochemical evaluation of the effects of paraffin section storage on biomarker stability. *Vet. Pathol.* 2014, 51, 102–109. [CrossRef]

28. Chen, H.; Fang, Q.Q.; Wang, B. The age of paraffin block influences biomarker levels in archival breast cancer samples. *Oncol. Lett.* 2020, 20, 525–532. [CrossRef]

29. Geisler, J.P.; Geisler, H.E.; Wiemann, M.C.; Zhou, Z.; Miller, G.A.; Crabtree, W. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. *Gynecol. Oncol.* 1999, 74, 468–471. [CrossRef]

30. Alvarez, T.; Miller, E.; Duska, L.; Oliva, E. Molecular profile of grade 3 endometrioid endometrial carcinoma: Is it a type I or type II endometrial carcinoma? *Am. J. Surg. Pathol.* 2012, 36, 753–761. [CrossRef]

31. Muinelo-Romay, L.; Colas, E.; Barbazan, J.; Alonso-Alconada, L.; Alonso-Nocelo, M.; Bouso, M.; Curiel, T.; Cueva, J.; Anido, U.; Forteza, J.; et al. High risk endometrial carcinoma profiling identifies TGF-b1 as a key factor in the initiation of tumor invasion. *Mol. Cancer Ther.* 2011, 10, 1357–1366. [CrossRef] [PubMed]

32. Wang, Y.; Yu, M.; Yang, J.X.; Cao, D.Y.; Shen, K.; Lang, J.H. Clinicopathological and survival analysis of uterine papillary serous carcinoma: A single institutional review of 106 cases. *Cancer Manag. Res.* 2018, 10, 4915–4928. [CrossRef] [PubMed]

33. Salvesen, H.B.; Haldorsen, I.S.; Trovik, J. Markers for individualised therapy in endometrial carcinoma. *Lancet Oncol.* 2012, 13, e353–e361. [CrossRef]

34. Raffone, A.; Troisi, J.; Boccia, D.; Travaglino, A.; Capuano, G.; Insabato, L.; Mollo, A.; Guida, M.; Zullo, F. Metabolomics in endometrial cancer: A systematic review. *Acta Obstet. Et Gynecol. Scand.* 2020, 99, 1135–1146. [CrossRef]

35. Njoku, K.; Sutton, C.J.; Whetton, A.D.; Crosbie, E.J. Metabolic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer. *Metabolites* 2020, 10, 314. [CrossRef]

36. Moon, Y.; Choi, S.M.; Chang, S.; Park, B.; Lee, S.; Lee, M.-O.; Choi, H.-S.; Park, H. Chenodeoxycholic Acid Reduces Hypoxia Inducible Factor-1α Protein and Its Target Genes. *PLOS ONE* 2015, 10, e0130911.

37. Carrasco, S.; Mérida, I. Diacylglycerol, when simplicity becomes complex. *Trends Biochem. Sci.* 2007, 32, 27–36. [CrossRef]

38. Almena, M.; Mérida, I. Shaping up the membrane: Diacylglycerol coordinates spatial orientation of signaling. *Trends Biochem. Sci.* 2011, 36, 593–603. [CrossRef]

39. Sakane, F.; Hoshino, F.; Murakami, C. New Era of Diacylglycerol Kinase, Phosphatidic Acid and Phosphatidic Acid-Binding Protein. *Int. J. Mol. Sci.* 2020, 21, 6794. [CrossRef]

40. Mérida, I.; Avila-Flores, A.; Merino, E. Diacylglycerol kinases: At the hub of cell signalling. *Biochem. J.* 2008, 409, 1–18. [CrossRef]

41. Peng, H.; Wang, Y.; Luo, W. Multifaceted role of branched-chain amino acid metabolism in cancer. *Oncogene* 2020, 39, 6747–6756. [CrossRef] [PubMed]

42. Troisi, J.; Sarno, L.; Landolfi, A.; Scala, G.; Martinelli, P.; Venturella, R.; Di Cello, A.; Zullo, F.; Guida, M. Metabolic Signature of Endometrial Cancer. *J. Proteome Res.* 2018, 17, 804–812. [CrossRef] [PubMed]

43. Ihata, Y.; Miyagi, E.; Numazaki, R.; Muramatsu, T.; Imaizumi, A.; Yamamoto, H.; Yamakado, M.; Okamoto, N.; Hirahara, F. Amino acid profile index for early detection of endometrial cancer: Verification as a novel diagnostic marker. *Int. J. Clin. Oncol.* 2014, 19, 364–372. [CrossRef] [PubMed]

44. Audet-Delage, Y.; Villeneuve, L.; Grégoire, J.; Plante, M.; Guillemette, C. Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women. *Front. Endocrinol.* 2018, 9, 87. [CrossRef]

45. Wray, J.W.; Abeles, R.H. The methionine salvage pathway in Klebsiella pneumoniae and rat liver. Identification and characterization of two novel dioxygenases. *J. Biol. Chem.* 1995, 270, 3147–3153. [CrossRef]

46. Oram, S.W.; Ai, J.; Pagani, G.M.; Hitchens, M.R.; Stern, J.A.; Eggener, S.; Pins, M.; Cai, X.; Haleem, R.; et al. Expression encoding an aci-reductone dioxygenase-like protein in the rat prostate. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2018, 1864, 2793–2813. [CrossRef]

47. Qiang, L.; Cao, H.; Chen, J.; Weller, S.G.; Krueger, E.W.; Zhang, L.; Razidlo, G.L.; McNiven, M.A. Pancreatic tumor cell metastasis pathway in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2018, 218, 317–332. [CrossRef]

48. Su, L.; Yang, K.; Li, S.; Liu, C.; Han, J.; Zhang, Y.; Xu, G. Enolase-phosphatase 1 as a novel potential malignant glioma indicator promotes cell proliferation and migration. *Oncol. Rep.* 2018, 40, 2233–2241. [CrossRef]

49. Uhlen, M.; Björling, E.; Agaton, C.; Szyszgarto, C.A.-K.; Amini, B.; Anderssen, E.; Andersson, A.-C.; Angelidou, P.; Asplund, A.; Asplund, C.; et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. *Mol. Cell. Proteom.* 2005, 4, 1920–1932. [CrossRef]

50. Lane, D.J.; Bae, D.-H.; Siafakas, A.R.; Rahmanto, Y.S.; Al-Akra, L.; Jansson, P.; Casero, R.; Richardson, D.R. Coupling of the polyamine and iron metabolism pathways in the regulation of proliferation: Mechanistic links to alterations in key polyamine biosynthetic and catabolic enzymes. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2018, 1864, 2793–2813. [CrossRef]

51. Mirza, A.; Wu, Q.; Wang, L.; McLeanahan, T.; Bishop, W.R.; Gheyas, F.; Ding, W.; Hutchins, B.; Hockenberry, T.; Kirschmeier, P.; et al. Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. *Oncogene* 2003, 22, 3645–3654. [CrossRef] [PubMed]

52. Oram, S.; Jiang, F.; Cai, X.; Haleem, R.; Dincer, Z.; Wang, Z. Identification and characterization of an androgen-responsive gene encoding an aci-reductone dioxygenase-like protein in the rat prostate. *Endocrinology* 2004, 145, 1933–1942. [CrossRef] [PubMed]
53. Pallares, J.; Llobet, D.; Santacana, M.; Eritja, N.; Velasco, A.; Cuevas, D.; Lopez, S.; Palomar-Asenjo, V.; Yeramian, A.; Dolcet, X.; et al. CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation. Am. J. Pathol. 2009, 174, 287–296. [CrossRef]

54. Pratt, J.; Iddir, M.; Bourgault, S.; Annabi, B. Evidence of MTCBP-1 interaction with the cytoplasmic domain of MT1-MMP: Implications in the autophagy cell index of high-grade glioblastoma. Mol. Carcinog. 2016, 55, 148–160. [CrossRef] [PubMed]